"What are allergies?
Allergies occur when the body's immune system responds to a substance it considers an "invader." Substances that provoke the immune system into an allergic response are known as allergens. There is no such thing as a"...
Like other topical corticosteroids, fluocinolone acetonide has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2
Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusion of topical corticosteroids can enhance penetration. Topical corticosteroids can be absorbed from normal intact skin. Also, inflammation and/or other disease processes in the skin can increase percutaneous absorption.
DermOtic® Oil (fluocinolone acetonide oil ear drops) is in the low to medium range of potency as compared with other topical corticosteroids.
Efficacy in a placebo-controlled study for the treatment of chronic eczematous external otitis on 154 patients (adults and children 2 years of age and older) treated with five drops per ear of DermOtic® Oil (fluocinolone acetonide oil ear drops) twice daily, after 7 days of treatment, showed DermOtic® Oil (fluocinolone acetonide oil ear drops) to be superior to placebo in clearing the signs and symptoms of eczematous external otitis.
Clinical safety studies were conducted on the same formulation of fluocinolone acetonide oil 0.01%, marketed as Derma-Smoothe/FS Topical Oil®. Open-label safety studies on 33 children (20 subjects ages 2 to 6 years, 13 subjects ages 7 to 12 years) with moderate to severe stable atopic dermatitis, and baseline body surface area involvement greater than 75% in 18 patients, and 50% to 75% in 15 patients, were treated with Derma-Smoothe/FS Topical Oil® twice daily for 4 weeks. Morning pre-stimulation cortisol level and post-Cortrosyn stimulation cortisol level were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. At the end of treatment, 4 out of 18 subjects aged 2 to 5 years showed low pre-stimulation cortisol levels (3.2 to 6.6μg/dL; normal: cortisol > 7μg/dL) but all had normal responses to 0.25 mg of Cortrosyn stimulation (cortisol > 18 μg/dL).
A clinical study was conducted to assess the safety of Derma-Smoothe/FS Topical Oil®, which contains refined peanut oil, on subjects with known peanut allergies. The study enrolled 13 patients with atopic dermatitis, 6 to 17 years of age. Of the 13 patients, 9 were Radioallergosorbent Test (RAST) positive to peanuts and 4 had no peanut sensitivity (controls). The study evaluated the responses to both prick test and patch test utilizing peanut oil NF, Derma-Smoothe/FS Topical Oil® and histamine/saline controls on the 13 individuals. These subjects were also treated with Derma-Smoothe/FS Topical Oil® twice daily for 7 days. Prick test and patch test results for all 13 patients were negative to Derma-Smoothe/FS Topical Oil® and the refined peanut oil. One of the 9 peanut-sensitive patients experienced an exacerbation of atopic dermatitis after 5 days of Derma-Smoothe/FS Topical Oil® use. Importantly, the bulk peanut oil NF, used in Derma-Smoothe/FS Topical Oil® is heated at 475°F for at least 15 minutes, which should provide for adequate decomposition of allergenic proteins.
Last reviewed on RxList: 12/21/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional DermOtic Oil Information
DermOtic Oil - User Reviews
DermOtic Oil User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.